Drugs Targeting BRAF

  • Mekinist (trametinib) plus Taflinar (dabrafenib) – approved in combination for stage 4 NSCLC patients with the BRAF V600E change as detected by a biomarker test.
  • Braftovi (encorafenib) plus Mektovi (binimetinib) – approved for adults with stage 4 metastatic NSCLC with a BRAF V600E change as detected by an FDA-approved biomarker test.